PUBLICATION

2022.07.20

Drug Efficacy Study in the STAM™ Model Published in Translational Oncology

SMC is proud to announce that Kurume University (JPN) has published the results of their study using our STAM™ model in Translational Oncology.

 

Title “Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments

 

In this study, the authors evaluated the anti-tumor effect of combining sorafenib and S-1, a chemotherapeutic agent, in the STAM™ model.

 

As demonstrated in this paper, it is possible to study the effects of your compound in the STAM™ model as both a monotherapy as well as in combination therapy.

 

 

For detailed information, see the below URL.

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments (ScienceDirect)

 

 

Additionally, we can also suggest studies based on our many years of experience in both the STAM™ model, as well in other models, so please do not hesitate to contact us if you would like to learn more.

 

 

■About our STAM™ model mouse